Literature DB >> 2101480

Recombinant attenuated Vibrio cholerae strains used as live oral vaccines.

J B Kaper1, M M Levine.   

Abstract

Although great strides have been made in the development of recombinant attenuated Vibrio cholerae vaccine strains, the task has not been as simple as once imagined. The initial vaccine candidates proved to be unexpectedly reactogenic but further derivatives, such as CVD103-HgR, are well-tolerated, immunogenic and protective after a single dose. In addition, this strain carries a selectable marker to distinguish it from wild strains and has been evaluated in a practical, lyophilized formulation (Levine et al., 1988b). While CVD103-HgR is being further evaluated in expanded trials, we are also investigating a new secretogenic factor which could possibly explain the diarrhoea seen with the earlier vaccine strains. Hopefully, these studies will achieve the long-sought goal of a safe and effective vaccine for the prevention of cholera.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2101480     DOI: 10.1016/0923-2508(90)90128-d

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  10 in total

1.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors:  K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

2.  Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults.

Authors:  S J Cryz; M M Levine; G Losonsky; J B Kaper; B Althaus
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 3.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

Review 4.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

5.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

6.  PCR-based detection of Vibrio cholerae O139 Bengal with sequences encoding glycosyltransferases.

Authors:  S C Arya
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

7.  Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.

Authors:  E Gotuzzo; B Butron; C Seas; M Penny; R Ruiz; G Losonsky; C F Lanata; S S Wasserman; E Salazar; J B Kaper
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

Authors:  R Lagos; A Avendaño; V Prado; I Horwitz; S Wasserman; G Losonsky; S Cryz; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.

Authors:  Wilbur H Chen; Mitchell B Cohen; Beth D Kirkpatrick; Rebecca C Brady; David Galloway; Marc Gurwith; Robert H Hall; Robert A Kessler; Michael Lock; Douglas Haney; Caroline E Lyon; Marcela F Pasetti; Jakub K Simon; Flora Szabo; Sharon Tennant; Myron M Levine
Journal:  Clin Infect Dis       Date:  2016-03-21       Impact factor: 9.079

Review 10.  Live bacterial vaccine vectors: an overview.

Authors:  Adilson José da Silva; Teresa Cristina Zangirolami; Maria Teresa Marques Novo-Mansur; Roberto de Campos Giordano; Elizabeth Angélica Leme Martins
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.